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afflnnative-action program known as Imi Ho 'ala (Those Who Seek 
to Heal). This Program's efforts have contributed to the promotion 
of diversity within JABSOM's student population by providing 
opportunities in medicine for Native Hawaiians, Filipinos, Samo-
ans, residents of the US-Affiliated Pacific Islands (Marshallese, 
Pohnpeians, Kosraeans, Y apese, Chamorros, Palauans) aud South-
East Asian immigrants. In 25 years, 337 have been accepted into the 
Program. Seventy-fourpercent or 123 students have graduated from 
JABSOM. Others have become nurses, pubic health workers, medi-
cal technologists and other health specialties. 
For twenty-five years, the University of Hawaii John A. Burns 
School of Medicine (JABSOM) has successfully conducted an 
A primary feature of the Program is to train physicians who will 
serve the socially, economically, and educationally disadvantaged 
populations. There is a desperate need for physicians who identify 
themselves with these populations to deliver culturally competent 
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and effective health care. This is not only evi-
dent in the Pacific butin our entire nation. At the 
1996 Annual Meeting of the Association of 
American Medical Colleges (AAMC), Dr Jor-
dan J. Cohen, President of the AAMC, stated, 
"Learning how to deliver culturally competent 
care means learning medicine ... from faculty 
who are themselves emblematic of society's 
diversity. Textbooks alone just won't cut it" 
(1996, p 4). A sequel to this goal is the develop-
ment of physician leaders who will not only 
contribute to the total welfare of the community 
in which they fmd themselves, but become 
teachers in medicine. 
Graduates have also returned to serve as 
faculty at JABSOM. They teach in the class-
rooms as well as in the community hospitals and 
clinics. Imi Ho' ola graduates comprise 2 per-
cent of the compensated faculty at JABSOM. 
Two graduates from Imi Ho'ola are Chairper-
sons for the Department of Psychiatry and the 
Department ofFamily Practice and Community 
Medicine. In addition, Imi Ho 'ola alumni par-
ticipate in recruitment activities at the high 
school and university levels for students who 
will augment their numbers as well as replace 
them in the vital role of serving those least 
represented ethnic groups in Hawaii. As physi-
cians, these graduates serve as role models to 
those who have an exceptional desire and moti-
vation toward a medical career. An example is 
Dr Phillip Reyes, the Co-Medical Director for 
the Molokai General Hospital. Born and raised 
on the island of Molokai, Dr Reyes provides 
needed primary care services to the people of 
Molokai. In addition, he works in partnership 
with the schools in promoting health careers 
among the youth. 
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Finally, the Program is mindful that it must not lose sight of the
need to recognize their most important resource and responsibility,
the community which the graduates serve. Currently, sixty-two
percent of the Imi Ho ‘ola graduates are practicing in rural areas of
Oahu and the Neighbor Islands. To ensure the relationship with the
community, a community advisory committee has functioned since
the inception of the Program in 1973 to guide the Program. Commit
tee members include lawyers, psychologists, bankers, teachers and
graduates of the program.
Imi Ho ‘ola is fulfilling the mission of the John A. Bums School
of Medicine by teaching and training high quality physicians for
Hawaii and the Pacific, thereby promoting diversity in the medical
profession.
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Managed Care Concerns
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There are many advantages for the physician to participate in the
various managed care entities in our state. However, there are also
some problems at the root of all managed care participation. The
problems present themselves in subtle ways, that are sometimes not
recognized as problems by physicians. These problems are the result
of various Sections and Provisions of the Participating Provider
Agreement that is signed in order to participate in a managed care
organization (MCO).
Time and time again in reviewing MCO contracts the same land
mines are found present in the contracts. It is necessary that all
physicians carefully read the contracts received from an MCO, and
understand what commitment is being made by your signature on
the contract. There are several common clauses that might be found
in a proposed agreement which are likely to cause trouble in various
ways. When these clauses are identified in managed care agree
ments, consider asking whether the subj ectmatter contained in these
clauses is really necessary to address in the managed care relation
ship. Ifnot, they need not be in the agreement and should be removed
before the agreement is signed. Seven areas ofconcern that are often
found in many contracts which can be problematic include:
1. General Offsets and Adjustments. Provider agrees to autho
rize Company to deduct moneys that may otherwise be due and
payable to Provider from any outstanding moneys that Provider
may, for any reason, owe to Company. Provider agrees that
Company may make retroactive adjustments to the payment
schedule outlined in the agreement. This provision gives the
MCO a free hand to do whatever accounting it desires and
deduct moneys from a physician or physician group in its sole
discretion without a requirement to account to the physician or
physician group and explain such deductions.
2. Litigation. In the event of any litigation between the parties
arising out of or related to this Agreement, the prevailing party
shall be entitled to recover from the other party its reasonable
attorney’s fees and cost of litigation, including, without limita
tion, any expert witness fees. This clause seems designed to
appeal to the unsophisticated physician who abhors litigation
and has not stopped to consider that he or she is already greatly
disadvantaged in any potential controversy with the company,
since the MCO hasfar more to spend in legalfees. This clause
would simply up the ante by potentially doubling (at least) a
physician’s cost andfurther chill anyprospectfor thephysician
to obtain relief in a court of law.
3. Noninterference with Members. During the term of this
Agreement, Provider and its Qualified Physician shall not
advise or counsel an Enrollee to dis-enroll from Company’s
Plan and will not directly or indirectly solicit any Enrollee to
enroll in any other MCO or similar Health care service plan or
insurance program. No matter how it is dressed up, provisions
Public Service Announcements
American Cancer Society Seeking Volunteers.— Volun
teers with medical knowledge needed to staff and man the
library and a call-in telephone information line. These people
will be trained by the American Cancer Society, and will be
responsible for giving out cancer information to walk-ins and
callers. For further information call Susan Jacobs at the
American Cancer Society, 595-7500 ext. 202.
Volunteers needed for Angels on Wheels, drivers to take
cancer patients to and from their doctor/cancer therapy
appointments. To volunteer, contact the American Cancer
Society office in your area.
Volunteers needed at all American Cancer Society offices
to assist in clerical duties. Call to volunteer: Windward 262-
5124, Leeward 486-8404, and Honolulu 595-7544.
Seeking Helpline Volunteers.—The Honolulu Chapter of
the Alzheimer’s Assn. is seeking caring individuals to provide
information and referrals and emotional support to callers
needing assistance in coping with Alzheimer’s disease.
Volunteers will answer the telephone Helpline a minimum of
3-4 hours a week at our friendly Honolulu chapter office,
Monday-Friday, between the hours of 9 and 4 p.m. Orienta
tion and training will be provided. For further information orto
receive a volunteer application, please contact the Honolulu
Chapter at 591-2771.
Hospice Hawaii Volunteer Training.— 20-hr course at
Hospice Hawaii office. Wednesday, Sept. 9,6-9 p.m.; Satur
day, Sept.12, 8-5 p.m.; Saturday, Sept. 19,8-5 pm. Call 924-
9255, ext. 219 for more information.
Music Therapy Lectures Aug. 22.—Open to the public,
held at Hospice Hawaii office, call Barb Shirland, 924-9255
ext. 209. Featuring: Dr. Deforia Lane and Daniel Kobialka.
The Music Therapy Program involves both listening and
participation and provides benefits in many areas including:
physicial, psychological, social and spiritual. Founded in
1979, Hospice Hawaii is a non-profit organization that offers
medical, social, emotional, and spirftual support for patients
and families facing a terminal illness.
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